As FDA clears re­l­u­golix for uter­ine fi­broids, My­ovant, Pfiz­er gear up to take on Ab­b­Vie in com­mer­cial ri­val­ry

Pfiz­er and My­ovant have land­ed the key ap­proval need­ed to open up the women’s health side of their re­l­u­golix fran­chise, as the FDA clears a three-in-one pill to treat heavy men­stru­al bleed­ing as­so­ci­at­ed with uter­ine fi­broids.

Dubbed Myfem­bree, the drug — a com­bi­na­tion of re­l­u­golix, estra­di­ol and norethin­drone ac­etate — is the sec­ond in My­ovant’s mar­ket­ed port­fo­lio af­ter Or­govyx, which com­pris­es on­ly re­l­u­golix, was ap­proved for prostate can­cer in De­cem­ber. Both ther­a­pies and a third, for en­dometrio­sis, were all part of a $4.2 bil­lion com­mer­cial al­liance with Pfiz­er — lend­ing sig­nif­i­cant mus­cle as My­ovant goes up against Ab­b­Vie in a heat­ed mar­ket­ing bat­tle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER